WO2016182926A1 - Preparation of nanoemulsions - Google Patents
Preparation of nanoemulsions Download PDFInfo
- Publication number
- WO2016182926A1 WO2016182926A1 PCT/US2016/031263 US2016031263W WO2016182926A1 WO 2016182926 A1 WO2016182926 A1 WO 2016182926A1 US 2016031263 W US2016031263 W US 2016031263W WO 2016182926 A1 WO2016182926 A1 WO 2016182926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoemulsion
- ambient temperature
- water
- aqueous solution
- surfactant
- Prior art date
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 127
- 238000002360 preparation method Methods 0.000 title abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- 239000007864 aqueous solution Substances 0.000 claims description 46
- 239000004094 surface-active agent Substances 0.000 claims description 43
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 41
- 239000008240 homogeneous mixture Substances 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 238000003756 stirring Methods 0.000 claims description 33
- 230000002209 hydrophobic effect Effects 0.000 claims description 30
- 239000003607 modifier Substances 0.000 claims description 28
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 26
- 229920000053 polysorbate 80 Polymers 0.000 claims description 26
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002736 nonionic surfactant Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 abstract description 64
- 239000000126 substance Substances 0.000 abstract description 6
- 239000000341 volatile oil Substances 0.000 description 23
- 238000002156 mixing Methods 0.000 description 16
- 235000019502 Orange oil Nutrition 0.000 description 10
- -1 alkyl glucoside Chemical class 0.000 description 10
- 239000010502 orange oil Substances 0.000 description 10
- 235000003942 Rubus occidentalis Nutrition 0.000 description 9
- 244000111388 Rubus occidentalis Species 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 240000000560 Citrus x paradisi Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 5
- 229960004287 clofazimine Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- 235000004936 Bromus mango Nutrition 0.000 description 4
- 235000014826 Mangifera indica Nutrition 0.000 description 4
- 240000007228 Mangifera indica Species 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 235000009184 Spondias indica Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- PKBSGDQYUYBUDY-UHFFFAOYSA-N 1-nonacosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCO PKBSGDQYUYBUDY-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
- FRDAATYAJDYRNW-UHFFFAOYSA-N 3-methyl-3-pentanol Chemical compound CCC(C)(O)CC FRDAATYAJDYRNW-UHFFFAOYSA-N 0.000 description 2
- 244000152526 Agathosma crenulata Species 0.000 description 2
- 235000013388 Agathosma crenulata Nutrition 0.000 description 2
- 235000009269 Barosma crenulata Nutrition 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100026816 DNA-dependent metalloprotease SPRTN Human genes 0.000 description 2
- 101710175461 DNA-dependent metalloprotease SPRTN Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 2
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 240000009023 Myrrhis odorata Species 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 229940062650 buchu Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 description 2
- ULCZGKYHRYJXAU-UHFFFAOYSA-N heptacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCO ULCZGKYHRYJXAU-UHFFFAOYSA-N 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N nonadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ZEHYJZXQEQOSON-AATRIKPKSA-N (e)-1-chloro-3-ethylpent-1-en-4-yn-3-ol Chemical compound CCC(O)(C#C)\C=C\Cl ZEHYJZXQEQOSON-AATRIKPKSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- 239000005968 1-Decanol Substances 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- XQQZRZQVBFHBHL-UHFFFAOYSA-N 12-crown-4 Chemical compound C1COCCOCCOCCO1 XQQZRZQVBFHBHL-UHFFFAOYSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000271309 Aquilaria crassna Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 241000016649 Copaifera officinalis Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- JLPDBLFIVFSOCC-UHFFFAOYSA-N Oleandrin Natural products O1C(C)C(O)C(OC)CC1OC1CC(CCC2C3(CC(C(C3(C)CCC32)C=2COC(=O)C=2)OC(C)=O)O)C3(C)CC1 JLPDBLFIVFSOCC-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 240000002629 Pelargonium odoratissimum Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002911 Salvia sclarea Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 240000003021 Tsuga heterophylla Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YSSSPARMOAYJTE-UHFFFAOYSA-N dibenzo-18-crown-6 Chemical compound O1CCOCCOC2=CC=CC=C2OCCOCCOC2=CC=CC=C21 YSSSPARMOAYJTE-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004447 ethchlorvynol Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 1
- 229960001062 icatibant Drugs 0.000 description 1
- 108700023918 icatibant Proteins 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 1
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 1
- 229950010050 oleandrin Drugs 0.000 description 1
- LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 description 1
- LBIYNOAMNIKVKF-UHFFFAOYSA-N palmitoleyl alcohol Natural products CCCCCCC=CCCCCCCCCO LBIYNOAMNIKVKF-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940087291 tridecyl alcohol Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Definitions
- compositions for the preparation of oil-in- water nanoemulsions, nanoemulsions produced thereby, and applications thereof are provided herein.
- methods are provided for preparation of nanoemulsions at ambient temperature and atmosphere pressure (e.g., in a conventional chemical reactor or mixer).
- aqueous solution and a homogeneous mixture comprising a nonionic surfactant and hydrophobic agent to form a nanoemulsion
- stirring the nanoemulsion to reduce average diameter of droplets in the nanoemulsion.
- the aqueous solution and the homogeneous mixture are combined at sufficiently slow enough rate to allow a nanoemulsion to form (e.g., the particular rate may depend upon the identity of the components and/or the volume to be added).
- the aqueous solution and the homogeneous mixture are combined over the course of greater than 5 minutes (e.g., 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, or more, or any rangers therein (e.g., 10-30 minutes)). In some embodiments, the
- nanoemulsion is stirred for greater than 1 hour (e.g., 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, or more, or ranges therein (e.g., 2-96 hours)) to reduce average diameter of droplets in the nanoemulsion.
- one or both of steps (a) and (b) is performed at ambient temperature and atmospheric pressure.
- both steps (a) and (b) are performed at ambient temperature and atmospheric pressure.
- the aqueous solution is distilled water. In some embodiments, the aqueous solution comprises buffer and/or salt. In some embodiments, the
- nanoemulsion formed in step (a) comprises an average droplet diameter of 40-150 nm.
- the average droplet diameter following step (b) is less than 20 nm.
- the average droplet diameter following step (b) is less than 10 nm.
- the average droplet diameter following step (b) is less than 5 nm.
- the hydrophobic agent is physiologically compatible.
- the hydrophobic agent is an oil.
- the surfactant is physiologically compatible.
- the surfactant is polysorbate 80 (e.g., Tween 80).
- the aqueous solution comprises a modifier and/or co-surfactant.
- the homogeneous mixture further comprises a modifier and/or co-surfactant.
- the modifier is physiologically compatible.
- the modifier is a viscosity modifier.
- the viscosity modifier is a viscosity -reduction agent.
- the viscosity -reduction agent is selected from the group comprising ethyl alcohol, isopropyl alcohol, and propylene glycol.
- the co-surfactant is physiologically compatible.
- the co-surfactant is PEG-400.
- compositions, nanoemulsions, and/or nanodroplets produced by the methods described herein.
- compositions, nanoemulsions, and/or nanodroplets produced by the methods described herein.
- compositions are formulated for administration or delivery to a subject (e.g., human or mammalian subject).
- Nanoemulsion refers to oil-in-water dispersions comprising nanometer scale oil-phase droplets in an aqueous phase.
- Nanoemulsions include oil droplets ("nanodroplets") of 200 nm or less diameter (e.g., ⁇ 180 nm, ⁇ 160 nm, ⁇ 140 nm, ⁇ 120 nm ⁇ 100 nm, ⁇ 80 nm, ⁇ 60 nm, ⁇ 40 nm, ⁇ 30 nm, ⁇ 20 nm, ⁇ 15 nm, ⁇ 10 nm, ⁇ 8 nm, ⁇ 6 nm, ⁇ 5 nm, or less) in aqueous solution.
- surfactant refers to a compound that, when included in a mixture, lowers the surface tension or interfacial tension between two liquids or between a liquid and a solid in the mixture. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, and/or dispersants.
- nonionic surfactant typically refers to uncharged long-chain (e.g., >8 carbons) alcohols.
- physiologically compatible refers to a material or agent having the characteristic of being non-toxic and otherwise well-tolerated by biological systems including upon topical or internal administration to a human subject.
- a substance may be termed physiologically compatible if the benefits of administration or consumption of the substance outweigh any toxicity or negative side effects.
- Atmospheric pressure refers to the magnitude of the air pressure at sea level, approximately 760 torr. Atmospheric pressure encompasses a range of aout 760 ⁇ 10% (e.g., 684 Torr, 692 Torr, 700 Torr, 708 Torr, 716 Torr, 724 Torr, 732 Torr, 740 Torr, 748 Torr, 756 Torr, 764 Torr, 772 Torr, 780 Torr, 788 Torr, 796 Torr, 804 Torr, 812 Torr, 820 Torr, 828 Torr, 836 Torr, or any ranges therebetween), particularly when variation is caused by weather, altitude, or other natural causes.
- 684 Torr, 692 Torr 700 Torr, 708 Torr, 716 Torr, 724 Torr, 732 Torr, 740 Torr, 748 Torr, 756 Torr, 764 Torr, 772 Torr, 780 Torr, 788 Torr, 796 Torr, 804 Tor
- ambient temperature refers to approximately 18-26
- °C e.g., 18, 19, 20, 21 , 22, 23, 24, 25, 26, or any ranges therebetween. Variation within or around that range is particularly acceptable when the variation is caused by natural conditions or the environmental (e.g., room) temperature, rather than specific heating or cooling of a reaction vessel.
- compositions for the preparation of oil-in- water nanoemulsions, nanoemulsions produced thereby, and applications thereof are provided herein.
- methods are provided for preparation of nanoemulsions at ambient temperature (e.g., 20-26°C) and atmosphere pressure (e.g., in a conventional chemical reactor or mixer).
- methods generate highly clear and transparent oil-in- water nanoemulsions (e.g., in large quantity (e.g., >5L (e.g., 10 L, 15 L, 20 L, 25 L, 30 L, 40 L, 50 L, 60 L, 70 L, 80 L, 90 L, 100 L or more)).
- Processes find use in the preparation of delivery vehicles for a variety of cosmetics, personal care materials, medicines, etc.
- processes of preparing nanoemulsions comprise the slow addition an aqueous solution (e.g., water, distilled water, water and salt/buffer, etc.) to a homogeneous mixture comprising a nonionic surfactant (e.g., Tween 80, alkyl glucoside, PEG-400, etc.) and a hydrophobic agent (e.g., insoluble or poorly soluble in water).
- a homogeneous mixture e.g., comprising a nonionic surfactant and a hydrophobic agent
- a homogeneous mixture is slowly added to an aqueous solution.
- slow addition e.g., of aqueous solution to the homogeneous mixture, of the homogeneous mixture to the aqueous solution, etc.
- slow addition is at a sufficiently low enough rate to allow formation of moderately sized nanodroplets (e.g., 200 nm, 180 nm, 160 nm, 140 nm, 120 nm, 100 nm, 80 nm, 60 nm, 40 nm, or any suitable ranges therebetween (e.g., 60-120 nm).
- slow addition is at a rate less than 5 g/min., less than 2 g/min., less than 1 g/min., less than 0.5 g/min., or less than 0.2 g/min. (e.g., 5 g/min., 4 g/min., 3 g/min., 2 g/min., 1 g/min., 0.8 g/min., 0.6 g/min., 0.5 g/min., 0.4 g/min., 0.3 g/min. , ⁇ 0.2 g/min., 0.1 g/min., 0.08 g/min.
- 5 g/min. less than 2 g/min., less than 1 g/min., less than 0.5 g/min., or less than 0.2 g/min.
- slow addition is at a rate of 1 -30 g/min (e.g., 1 g/min, 2 g/min, 3 g/min, 4 g/min, 5 g/min, 6 g/min, 7 g/min, 8 g/min, 9 g/min, 10 g/min, 15 g/min, 20 g/min, 25 g/min, 30 g/min, or any suitable ranges therebetween (e.g., 4-20 g/min, etc.)).
- slow addition is at a rate of 20-200 g/min (e.g., 20 g/min, 30 g/min, 40 g/min, 50 g/min, 60 g/min, 70 g/min, 80 g/min, 90 g/min, 100 g/min, 120 g/min, 140 g/min, 160 g/min, 180 g/min, 200 g/min, or any suitable ranges therebetween (e.g., 40-120 g/min, etc.)).
- 20-200 g/min e.g., 20 g/min, 30 g/min, 40 g/min, 50 g/min, 60 g/min, 70 g/min, 80 g/min, 90 g/min, 100 g/min, 120 g/min, 140 g/min, 160 g/min, 180 g/min, 200 g/min, or any suitable ranges therebetween (e.g., 40-120 g/min, etc.)).
- processes further comprise the addition of one or more of a modifier (e.g., propylene glycol, isopropyl alcohol, etc.), and/or a co-surfactant (e.g., PEG-400).
- a homogeneous mixture comprises: a surfactant, co-surfactant, and hydrophobic agent; surfactant, modifier, and hydrophobic agent; or surfactant, co-surfactant, modifier, and hydrophobic agent.
- the aqueous phase comprises: water (e.g., distilled or with buffer and/or salt); water and surfactant (or co-surfactant); water and modifier; or water, modifier, and surfactant (or co-surfactant).
- suitable surfactants and co-surfactants for use in the processes, mixtures, and compositions described herein are nonionic.
- Suitable surfactants (and co-surfactants) include, but are not limited to: polyoxy ethylene glycol alkyl ethers (e.g., CH 3 -(CH 2 )io i6-(0-C 2 H 4 )i 25-OH, octaethylene glycol
- polyoxypropylene glycol alkyl ethers e.g., CH 3 -(CH 2 )io-i6-(0-C 3 H 6 )i-25-OH
- glucoside alkyl ethers e.g., CH 3 -(CH 2 )io-i6-(0-glucoside)i_3-OH, decyl glucoside, lauryl glucoside, octyl glucoside, etc.
- polyoxyethylene glycol octylphenol ethers e.g., C 8 Hi 7 -(C 6 H 4 )-(0- C 2 H 4 )i_25-OH
- Triton X-100 e.g., polyethylene glycol p-(l, l ,3,3-tetramethylbutyl)- phenyl ether), etc.
- polyoxyethylene glycol alkyl alkyl ethers e.g., CH 3 -(CH 2 )io
- Suitable modifiers include, but are not limited to: propylene glycol, ethanol, isopropanol, butanol, polypropylene glycol, cellulose ethers, etc. Other modifiers that are tolerated in the system and the products and applications utilizing the
- modifier could also be long chain (greater than or equal to C4) fatty alcohols, such as: tert-butyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, ethchlorvynol, octanol, 2-ethylhexanol, 1 -nonanol, 1 - decanol, undecanol, dodecanol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleyl alcohol, heptadecyl alcohol, stearyl alcohol, nonadecyl alcohol, arachidyl alcohol, heneicosyl alcohol, behenyl alcohol, eucyl alcohol, lignoceryl alcohol, ceryl alcohol, 1-heptacosanol, montanyl alcohol, 1 -nonacosanol, myricyl alcohol,
- fatty alcohols such as: tert-
- Alcohols for example, commonly used sugar alcohol could also be applied. This includes, but not limited to: arabitol, erythritol, glycerol, hydrogenated starch hydrolysates (HSH), isomalt, lactitol, maltitol, mannitol, sorbitol, xylitol, sucrose, etc.
- HSH hydrogenated starch hydrolysates
- modifier could be crown ethers, such as (but not limited to) 12- crown-4, 15-crown-5, 18-crown-6, dibenzo-18-crown-6, and diaza-18-crown-6.
- the modifier is a "viscosity modifier" and is included to adjust viscosity (e.g., to increase/decrease viscosity of the homogeneous mixture or nanoemulsion).
- the viscosity modifier is a "viscosity reduction agent” and is included to reduce the viscosity (e.g., of the homogeneous mixture, aqueous solution, and/or nanoemulsion).
- suitable hydrophobic agents are oils, lipids, or other compositions that are non-miscible with water or have low miscibility with water.
- a hydrophobic agent is an active agent (e.g., having a desired property for which the nanoemulsion is a delivery vehicle).
- the hydrophobic agent is the active agent of the nanoemulsion.
- Suitable hydrophobic agents include, but are not limited to, oils of the type of mineral oils, vegetable oils, animal oils, essential oils, synthetic oils, or mixtures thereof.
- a hydrophobic agent is an oil rich in triglycerides, such as safflower oil, soybean oil, sesame oil, camellia oil, cotton seed oil, medium chain triglycerides, their mixtures or mixtures with other vegetable oils.
- a hydrophobic agent is a poorly water-soluble drugs, such as: paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole,
- a hydrophobic agent comprises one or more essential oils, such as those derived from berries (e.g., allspice, juniper, etc.), seeds (e.g., almond, anise, buchu, celery, cumin, nutmeg oil, etc.), bark (e.g., cassia, cinnamon, sassafras, etc.), wood
- rhizome e.g., galangal, ginger, etc.
- leaves e.g., basil, bay leaf, buchu, cinnamon, common sage, eucalyptus, guava, lemon grass, melaleuca, oregano, patchouli, peppermint, pine, rosemary, spearmint, tea tree, thyme, tsuga, wintergreen, etc.
- resin e.g., benzoin, copaiba, frankincense, myrrh, etc.
- flowers e.g., cannabis, chamomile, clary sage, clove, scented geranium, hops, hyssop, jasmine, lavender, manuka, marjoram, orange, rose, ylang-ylang, etc.
- peel e.g., bergamot, grapefruit, lemon, lime, orange, tangerine, etc.
- a hydrophobic agent is peptide or protein drug such as: insulin, leuprorelin, bortezomib, goserelin, bivalirudin, eptifibatide, glatiramer, liraglutide, telaprevir, boceprevir, icatibant, etc.
- the active agent is the hydrophobic agent.
- an additional active agent is added.
- an active agent is dissolved or placed in solution in a hydrophobic carrier (e.g., vegetable oil, etc.).
- a hydrophobic carrier e.g., vegetable oil, etc.
- reagents, solutions, mixtures, etc. are mixed, stirred, shaken, or otherwise combined. Unless otherwise specified, combination of reagents occurs passively (e.g., by diffusion), or reagents are actively combined by mechanical intervention (e.g., stirring, agitating, etc.) or other processes (e.g., soni cation, etc.).
- the rate of stiring is at least 1 rpm and not exceeding 5000 rpms (e.g., 1 rpm, 2 rpms, 5 rpms, 10 rpms, 20 rpms, 50 rpms, 100 rpms, 200 rpms, 500 rpms, 1000 rpms, 2000 rpms, 2500 rpms, 3000 rpms, 4000, rpms, 5000 rpms or any suitable ranges therebetween).
- sonication is employed (e.g., when initially mixing the reagents to form the homogeneous mixture).
- vigorous stirring e.g., 1000-2000 rpms, about 1500 rpms, etc.
- gentle stirring e.g., 100 to 600 rpms (e.g., 100 rpms, 200 rpms, 300 rpms, 400 rpms, 500 rpms, 600 rpms or any suitable ranges therebetween (e.g., 200-500 rpms)) is employed (e.g., to induce a reduction in nanodroplet size).
- formation of nanoemulsion according to the embodiments described herein utilizes a homogeneous mixture comprising at least a hydrophobic agent (which is mixed with an aqueous solution (e.g., in a subsequent step)).
- methods comprise combining (e.g., mixing) a nonionic surfactant (e.g., Tween 80), a co-surfactant (e.g., PEG-400), and/or a modifier (e.g., propylene glycol isopropyl alcohol, etc.) with a hydrophobic agent (e.g., a hydrophobic agent having a desired property (e.g., cosmetic property, wellness- promotion property, therapeutic/prophalactic property, etc.).
- a nonionic surfactant, co-surfactant, and/or modifier are combined into a homogeneous mixture before adding the hydrophobic agent.
- nonionic surfactant, co-surfactant, modifier, and hydrophobic agent and added together and then homogenized.
- nonionic surfactant, co- surfactant, modifier, and/or hydrophobic agent are mixed (e.g., stirred) or allowed to mix at ambient temperature and atmospheric pressure to provide homogeneous mixture. Formation of an aqueous solution (step Ob)
- formation of nanoemulsion according to the embodiments described herein utilizes an aqueous solution (which is mixed with a homogeneous mixture comprising a hydrophobic agent (e.g., in a subsequent step)).
- the aqueous solution described in embodiments herein comprises, consists, or consists essentially of water (with common salt, metal, and oxide impurities) or distilled water.
- the aqueous solution further comprises one or more suitable buffers, salts, etc.
- the aqueous solution is not limited by the type or presence of cations (e.g., (NH 4 +, Ca , Mg , Na , Fe , Fe , etc.), anions (CI “ , Br “ , C0 3 2" , P0 4 3” , S0 4 2” , etc.), buffers (e.g., TRIS, MOPS, HEPES, etc.), or other solutes in the aqueous solution, unless an embodiment specifies otherwise.
- cations e.g., (NH 4 +, Ca , Mg , Na , Fe , Fe , etc.
- anions CI “ , Br “ , C0 3 2" , P0 4 3” , S0 4 2” , etc.
- buffers e.g., TRIS, MOPS, HEPES, etc.
- the aqueous solution further comprises a surfactant, co- surfactant, and/or modifier.
- a surfactant, co- surfactant, and/or modifier are mixed with water and any other suitable solutes to generate an aqueous solution.
- an aqueous mixture e.g., water and one or more undissolved components (e.g., surfactant, co-surfactant, and/or modifier) is used. Formation of nanoemulsion (step 1)
- an aqueous solution e.g., water, distilled water, water and buffer/salt
- aqueous solution e.g., water, distilled water, water and buffer/salt
- the homogeneous mixture e.g., at ambient temperature (e.g., 18 °C, 19 °C, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, 25 °C, 26 °C, 27 °C, 28 °C, and any suitable ranges therein (e.g., 20-26 °C, 22-24 °C)) and atmosphere pressure (e.g., 684-836 Torr (e.g., 684 Torr, 700 Torr, 716 Torr, 732 Torr, 748 Torr, 764 Torr, 780 Torr, 796 Torr, 812 Torr, 828 Torr, 836 Torr, or ranges therebetween)) ).
- 684-836 Torr e.g., 684
- the aqueous solution is added with stirring, shaking, or other mechanical mixing. In some embodiments, the aqueous solution is added (e.g., dropwise) over the course of at least 5 minutes (e.g., 5 mia, 10 mia, 15 mia, 20 mia, 25 mia, 30 mia, 35 mia, 40 mia, 45 mia, 50 mia, 55 mia, 60 mia, 80 mia, 100 mia, 120 mia, >120 mia, or any suitable ranges therein (e.g., 20-40 mia, etc.).
- 5 minutes e.g., 5 mia, 10 mia, 15 mia, 20 mia, 25 mia, 30 mia, 35 mia, 40 mia, 45 mia, 50 mia, 55 mia, 60 mia, 80 mia, 100 mia, 120 mia, >120 mia, or any suitable ranges therein (e.g., 20-40 mia, etc.).
- aqueous solution is added at a suitable rate, as described herein (e.g., ⁇ 5 g/mia, ⁇ 2 g/mia, ⁇ 1 g/mia, ⁇ 0.5 g/mia, ⁇ 0.2 g/min, etc.).
- a fixed volume of aqueous solution is added (e.g., to achieve a particular ratio (e.g., with respect to another ingredient (e.g., surfactant, co-surfactant, modifier, hydrophobic agent, etc.)).
- aqueous solution is slowly added to the homogeneous mixture until a nanoemulsion forms (e.g., without concern as to the volume of the water added).
- the homogeneous mixture is added to an aqueous solution (e.g., water, distilled water, water and buffer/salt).
- the homogeneous mixture is added with stirring, shaking, or other mechanical mixing.
- the aqueous solution is added (e.g., drop wise) over the course of at least 5 minutes (e.g., 5 min., 10 min., 15 min., 20 min., 25 min., 30 min., 35 min., 40 min., 45 min., 50 min., 55 min., 60 min., 80 min., 100 min., 120 min., >120 min., or any suitable ranges therein (e.g., 20-40 min., etc.)).
- the homogeneous mixture is added at a suitable rate, as described herein (e.g., ⁇ 5 g/min., ⁇ 2 g/min., ⁇ 1 g/min., ⁇ 0.5 g/min., ⁇ 0.2 g/min, etc.).
- a suitable rate as described herein (e.g., ⁇ 5 g/min., ⁇ 2 g/min., ⁇ 1 g/min., ⁇ 0.5 g/min., ⁇ 0.2 g/min, etc.).
- a fixed volume of homogeneous mixture is added to a fixed volume of homogeneous mixture.
- homogeneous mixture is slowly added to a fixed volume of aqueous solution until a nanoemulsion forms (e.g., without concern as to the volume of the homogeneous mixture added).
- the end product of the above-described mixing of the homogenous mixture and aqueous solution is a nanoemulsion.
- the nanoemulsion is translucent.
- the end product of the initial addition/mixing of the homogenous mixture and aqueous solution is not transparent.
- the translucency but not transparency of the nanoemulsion indicates moderately-sized nanodroplets (e.g., 200 nm, 180 nm, 160 nm, 140 nm, 120 nm, 100 nm, 80 nm, 60 nm, 40 nm, or any suitable ranges therebetween (e.g., 60-120 nm).
- a nanoemultion produced by slow addition (with mixing/stirring) of aqueous solution to homogenous mixture (or vice versa) exhibits moderately-sized mean or median nanodroplets.
- such a nanoemulsion is produced in less than 1 hour (e.g., 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or any suitable ranges therein) of combining aqueous solution and homogenous mixture.
- the nanoemulsions comprising moderately-size nanodroplets are termed first-stage nanoemulsions (e.g., having not yet been exposed to further mixing/stirring to produce small (e.g., ⁇ 40 nm) or ultrasmall (e.g., ⁇ 10 nm) nanodroplets).
- first-stage nanoemulsions e.g., having not yet been exposed to further mixing/stirring to produce small (e.g., ⁇ 40 nm) or ultrasmall (e.g., ⁇ 10 nm) nanodroplets.
- a nanoemulsion e.g., of moderately-size nanodroplets, first-stage nanoemulsion, etc.
- continued mixing e.g., stirring, agitation, etc.
- mixing is continued in the same vessel.
- mixing is continued in a different vessel.
- continued mixing produces a highly clear and transparent.
- the transparency of the nanoemulsion indicates significant reduction of nanodroplet size (e.g., small (e.g., ⁇ 40 nm) or ultrasmall (e.g., ⁇ 10 nm) nanodroplets).
- mixing is carried out for at least 30 minutes (e.g., 30 min., 45 min., 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or more, or any suitable ranges therein (e.g., >4 hours, 2-24 hours, etc.)).
- mixing is carried out by vigorous stirring.
- mixing is carried out by moderate intensity stirring.
- mixing is carried out by gently stirring.
- co-surfactant and modifier are present in a
- this is particularly important for the preparation of nanoemulsions at ambient temperature (e.g., to save cost, for nanoemulsions made of reagents (e.g., hydrophobic agents) that do not tolerate elevated temperatures, etc.), because heat cannot be added to the system to reduce viscosity; although the embodiments are not limited to any particular mechanism of action and an understanding of the mechanism of action is not necessary to practice such embodiments.
- reagents e.g., hydrophobic agents
- ingredients e.g., hydrophobic agents
- only one nonionic surfactant e.g., no co-surfactant and/or modifier
- the use of elevated temperature e.g., 30°C or greater
- atmosphere pressure e.g., >800 Torr, >810 Torr, >820 Torr, >830 Torr, >840 Torr, >850 Torr, >875 Torr, >900 Torr, >950 Torr, >1000 Torr, >1100 Torr, >1200 Torr, 1300 Torr, 1400 Torr, 1500 Torr
- a single surfactant e.g., no co-surfactant and/or modifier
- This translucent nanoemulsion is then stirred at ambient temperature (or at elevated temperature) and atmosphere pressure (or elevated pressure) for a time ranging from hours (e.g., 2-20 hours) to days (e.g., 1 to 6 days) to generate the highly clear and transparent nanoemulsion.
- this single-surfactant formulation provides a very simple nanoemulsion system for further modification including combination with other ingredients.
- compositions described herein are provided as pharmaceutical, therapeutic, skin-care, hair-care, beauty, health, and/or wellness compositions.
- Compositions can be administered in a number of ways depending upon whether local or systemic administration is desired. Administration can be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional carriers aqueous, powder, or oily bases;
- compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable.
- Compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions that can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
- Formulations, which can conveniently be presented in unit dosage form can be prepared according to conventional techniques well known in the appropriate industries.
- compositions can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas.
- the compositions of the present invention can also be formulated as suspensions in aqueous, non-aqueous, oil-based, or mixed media. Suspensions can further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
- the suspension can also contain stabilizers.
- Compositions can be formulated and used as foams.
- Dosing and administration regimes may be tailored by a clinician or other individual skilled in the appropriate field, based upon well-known considerations including, but not limited to, the desired level of effect, the practical level of effect obtainable, side effects, cost, etc. Dosing may be once per day or multiple times per day for one or more consecutive days.
- mango essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0. lOg) and isopropyl alcohol (91% in water, 0. lOg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 3 days, a highly clear and transparent naonemulsion was obtained.
- mango essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0.06g) and isopropyl alcohol (91% in water, 0. lOg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
- vanilla essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0.1 Og) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
- Clofazimine 100 mg
- soybean oil 1.0 g
- PEG-400 0.1 g
- Tween 80 4.0 g
- water distilled, 4.0 g
- the above mentioned mixture of Clofazimine, soybean oil and PEG-400 was added very slowly at 50 °C in 30 min.
- the mixture was stirred at ambient temperature and atmosphere pressure overnight.
- the mixture was centrifuged and the highly clear and transparent nanoemulsion top was separated.
- the HPLC results showed the concentration of Clofazimine in this nanoemulsion is 0.45 mg/mL.
- Naoemulsion droplet size is at 6.5 ⁇ 1.1 nm (method is DLS, Dynamic Light
- Paclitaxel 22 mg was dissolved in the mixture of Tween 80 (0.88 g), PEG- 400 (1.23 g) and ethyl alcohol (absolute, 0.6 g) by sonication for 5 min. Then, to this solution, water (distilled) was added very slowly at ambient temperature and atmosphere. When the total mass reached 3 g, a translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure overnight, a highly clear and transparent naonemulsion was obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided herein are methods and compositions for the preparation of oil-inwater nanoemulsions, nanoemulsions produced thereby, and applications thereof. In particular, methods are provided for preparation of nanoemulsions at ambient temperature and atmosphere pressure (e.g., in a conventional chemical reactor or mixer).
Description
PREPARATION OF NANOEMULSIONS
CROSS REFERENCE TO RELATED APPLICATIONS
The present invention claims priority to U. S. Provisional Patent Application 62/158,568 filed May 8, 2015, which is incorporated by reference in its entirety.
FIELD
Provided herein are methods and compositions for the preparation of oil-in- water nanoemulsions, nanoemulsions produced thereby, and applications thereof. In particular, methods are provided for preparation of nanoemulsions at ambient temperature and atmosphere pressure (e.g., in a conventional chemical reactor or mixer).
BACKGROUND
Conventional techniques for preparing nanoemulsions of cosmetic ingredients, proteins, drugs, etc. include high pressure homogenization, ultrasonic treatment, or a phase inversion temperature process. Existing processes have many disadvantages including: high cost, unsuitability for labile reagents (e.g., material which cannot tolerate heat), inclusion of toxic reagents (e.g., quaternary ammonium salts), inability to produce transparent nanoemulsions, and larger droplet size (e.g., >100 nm).
SUMMARY
In some embodiments, provided herein are methods for preparing a nanoemulsion comprising: (a) combining: (i) an aqueous solution and (ii) a homogeneous mixture comprising a nonionic surfactant and hydrophobic agent to form a nanoemulsion; and (b) stirring the nanoemulsion to reduce average diameter of droplets in the nanoemulsion. In some embodiments, the aqueous solution and the homogeneous mixture are combined at sufficiently slow enough rate to allow a nanoemulsion to form (e.g., the particular rate may depend upon the identity of the components and/or the volume to be added). In some embodiments, the aqueous solution and the homogeneous mixture are combined over the course of greater than 5 minutes (e.g., 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, or more, or any rangers therein (e.g., 10-30 minutes)). In some embodiments, the
nanoemulsion is stirred for greater than 1 hour (e.g., 2 hours, 4 hours, 6 hours, 12
hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, or more, or ranges therein (e.g., 2-96 hours)) to reduce average diameter of droplets in the nanoemulsion. In some embodiments, one or both of steps (a) and (b) is performed at ambient temperature and atmospheric pressure. In some embodiments, both steps (a) and (b) are performed at ambient temperature and atmospheric pressure. In some
embodiments, the aqueous solution is distilled water. In some embodiments, the aqueous solution comprises buffer and/or salt. In some embodiments, the
nanoemulsion formed in step (a) comprises an average droplet diameter of 40-150 nm. In some embodiments, the average droplet diameter following step (b) is less than 20 nm. In some embodiments, the average droplet diameter following step (b) is less than 10 nm. In some embodiments, the average droplet diameter following step (b) is less than 5 nm. In some embodiments, the hydrophobic agent is physiologically compatible. In some embodiments, the hydrophobic agent is an oil. In some embodiments, the surfactant is physiologically compatible. In some embodiments, the surfactant is polysorbate 80 (e.g., Tween 80). In some embodiments, the aqueous solution comprises a modifier and/or co-surfactant. In some embodiments, the homogeneous mixture further comprises a modifier and/or co-surfactant. In some embodiments, the modifier is physiologically compatible. In some embodiments, the modifier is a viscosity modifier. In some embodiments, the viscosity modifier is a viscosity -reduction agent. In some embodiments, the viscosity -reduction agent is selected from the group comprising ethyl alcohol, isopropyl alcohol, and propylene glycol. In some embodiments, the co-surfactant is physiologically compatible. In some embodiments, the co-surfactant is PEG-400.
In some embodiments, provided herein are compositions, nanoemulsions, and/or nanodroplets produced by the methods described herein. In some
embodiments, compositions are formulated for administration or delivery to a subject (e.g., human or mammalian subject).
DEFINITIONS
As used herein, the term "nanoemulsion" refers to oil-in-water dispersions comprising nanometer scale oil-phase droplets in an aqueous phase. Nanoemulsions include oil droplets ("nanodroplets") of 200 nm or less diameter (e.g., <180 nm, <160 nm, <140 nm, <120 nm <100 nm, <80 nm, <60 nm, <40 nm, <30 nm, <20 nm, <15 nm, <10 nm, <8 nm, <6 nm, <5 nm, or less) in aqueous solution.
As used herein, the term "surfactant" refers to a compound that, when included in a mixture, lowers the surface tension or interfacial tension between two liquids or between a liquid and a solid in the mixture. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, and/or dispersants. The term "nonionic surfactant" typically refers to uncharged long-chain (e.g., >8 carbons) alcohols.
As used herein, the term "physiologically compatible" refers to a material or agent having the characteristic of being non-toxic and otherwise well-tolerated by biological systems including upon topical or internal administration to a human subject. A substance may be termed physiologically compatible if the benefits of administration or consumption of the substance outweigh any toxicity or negative side effects.
As used herein, the term "atmospheric pressure" refers to the magnitude of the air pressure at sea level, approximately 760 torr. Atmospheric pressure encompasses a range of aout 760 ±10% (e.g., 684 Torr, 692 Torr, 700 Torr, 708 Torr, 716 Torr, 724 Torr, 732 Torr, 740 Torr, 748 Torr, 756 Torr, 764 Torr, 772 Torr, 780 Torr, 788 Torr, 796 Torr, 804 Torr, 812 Torr, 820 Torr, 828 Torr, 836 Torr, or any ranges therebetween), particularly when variation is caused by weather, altitude, or other natural causes.
As used herein, the term "ambient temperature" refers to approximately 18-26
°C (e.g., 18, 19, 20, 21 , 22, 23, 24, 25, 26, or any ranges therebetween). Variation within or around that range is particularly acceptable when the variation is caused by natural conditions or the environmental (e.g., room) temperature, rather than specific heating or cooling of a reaction vessel.
DETAILED DESCRIPTION
Provided herein are methods and compositions for the preparation of oil-in- water nanoemulsions, nanoemulsions produced thereby, and applications thereof. In particular, methods are provided for preparation of nanoemulsions at ambient temperature (e.g., 20-26°C) and atmosphere pressure (e.g., in a conventional chemical reactor or mixer).
In some embodiments, methods generate highly clear and transparent oil-in- water nanoemulsions (e.g., in large quantity (e.g., >5L (e.g., 10 L, 15 L, 20 L, 25 L, 30 L, 40 L, 50 L, 60 L, 70 L, 80 L, 90 L, 100 L or more)). Processes find use in the
preparation of delivery vehicles for a variety of cosmetics, personal care materials, medicines, etc.
In some embodiments, processes of preparing nanoemulsions comprise the slow addition an aqueous solution (e.g., water, distilled water, water and salt/buffer, etc.) to a homogeneous mixture comprising a nonionic surfactant (e.g., Tween 80, alkyl glucoside, PEG-400, etc.) and a hydrophobic agent (e.g., insoluble or poorly soluble in water). In other embodiments, a homogeneous mixture (e.g., comprising a nonionic surfactant and a hydrophobic agent) is slowly added to an aqueous solution.
In some embodiments, slow addition (e.g., of aqueous solution to the homogeneous mixture, of the homogeneous mixture to the aqueous solution, etc.) is at a sufficiently low enough rate to allow formation of moderately sized nanodroplets (e.g., 200 nm, 180 nm, 160 nm, 140 nm, 120 nm, 100 nm, 80 nm, 60 nm, 40 nm, or any suitable ranges therebetween (e.g., 60-120 nm). In some embodiments in which 100 or fewer grams liquid are added, slow addition is at a rate less than 5 g/min., less than 2 g/min., less than 1 g/min., less than 0.5 g/min., or less than 0.2 g/min. (e.g., 5 g/min., 4 g/min., 3 g/min., 2 g/min., 1 g/min., 0.8 g/min., 0.6 g/min., 0.5 g/min., 0.4 g/min., 0.3 g/min. , <0.2 g/min., 0.1 g/min., 0.08 g/min. , 0.06 g/min., 0.04 g/min., 0.02 g/min., or any suitable ranges therebetween (e.g., 0.05-0.2 g/min, etc.)). In some embodiments in which 100-1000 grams of liquid are added, slow addition is at a rate of 1 -30 g/min (e.g., 1 g/min, 2 g/min, 3 g/min, 4 g/min, 5 g/min, 6 g/min, 7 g/min, 8 g/min, 9 g/min, 10 g/min, 15 g/min, 20 g/min, 25 g/min, 30 g/min, or any suitable ranges therebetween (e.g., 4-20 g/min, etc.)). In some embodiments in which 1 kilogram or more of liquid are added, slow addition is at a rate of 20-200 g/min (e.g., 20 g/min, 30 g/min, 40 g/min, 50 g/min, 60 g/min, 70 g/min, 80 g/min, 90 g/min, 100 g/min, 120 g/min, 140 g/min, 160 g/min, 180 g/min, 200 g/min, or any suitable ranges therebetween (e.g., 40-120 g/min, etc.)).
In some embodiments, processes further comprise the addition of one or more of a modifier (e.g., propylene glycol, isopropyl alcohol, etc.), and/or a co-surfactant (e.g., PEG-400). In some embodiments, a homogeneous mixture comprises: a surfactant, co-surfactant, and hydrophobic agent; surfactant, modifier, and hydrophobic agent; or surfactant, co-surfactant, modifier, and hydrophobic agent. In some embodiments, the aqueous phase comprises: water (e.g., distilled or with buffer and/or salt); water and surfactant (or co-surfactant); water and modifier; or water, modifier, and surfactant (or co-surfactant).
In some embodiments, suitable surfactants and co-surfactants for use in the processes, mixtures, and compositions described herein are nonionic. Suitable surfactants (and co-surfactants) include, but are not limited to: polyoxy ethylene glycol alkyl ethers (e.g., CH3-(CH2)io i6-(0-C2H4)i 25-OH, octaethylene glycol
monododecyl ether, pentaethylene glycol monododecyl ether, etc.), polyoxypropylene glycol alkyl ethers (e.g., CH3-(CH2)io-i6-(0-C3H6)i-25-OH), glucoside alkyl ethers (e.g., CH3-(CH2)io-i6-(0-glucoside)i_3-OH, decyl glucoside, lauryl glucoside, octyl glucoside, etc.), polyoxyethylene glycol octylphenol ethers (e.g., C8Hi7-(C6H4)-(0- C2H4)i_25-OH, Triton X-100 (e.g., polyethylene glycol p-(l, l ,3,3-tetramethylbutyl)- phenyl ether), etc.), polyoxyethylene glycol alkylphenol ethers (e.g., C9Hi9-(C6H )- (0-C2H4)i_25-OH, nonoxynol-9, etc.), glycerol alkyl esters (e.g., glyceryl laurate, etc.), polyoxyethylene glycol sorbitan alkyl esters (e.g., polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), polysorbate 80 (Tween 80), etc.), sorbitan alkyl esters, cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (e.g., poloxamers), polyethoxylated tallow amine (POEA), polyethylene glycols (e.g., PEG- 400, PEG-600, PEG-800, PEG-1000, PEG-2000, etc.), Spartan 20, Spartan 80, etc..
Suitable modifiers include, but are not limited to: propylene glycol, ethanol, isopropanol, butanol, polypropylene glycol, cellulose ethers, etc. Other modifiers that are tolerated in the system and the products and applications utilizing the
nanoemulsions are also contemplated. For example, modifier could also be long chain (greater than or equal to C4) fatty alcohols, such as: tert-butyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, ethchlorvynol, octanol, 2-ethylhexanol, 1 -nonanol, 1 - decanol, undecanol, dodecanol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoleyl alcohol, heptadecyl alcohol, stearyl alcohol, nonadecyl alcohol, arachidyl alcohol, heneicosyl alcohol, behenyl alcohol, eucyl alcohol, lignoceryl alcohol, ceryl alcohol, 1-heptacosanol, montanyl alcohol, 1 -nonacosanol, myricyl alcohol, 1 -dotriacontanol, geddyl alcohol, Cetearyl alcohol, etc. Other alcohols, for example, commonly used sugar alcohol could also be applied. This includes, but not limited to: arabitol, erythritol, glycerol, hydrogenated starch hydrolysates (HSH), isomalt, lactitol, maltitol, mannitol, sorbitol, xylitol, sucrose, etc. Other example of modifier could be crown ethers, such as (but not limited to) 12- crown-4, 15-crown-5, 18-crown-6, dibenzo-18-crown-6, and diaza-18-crown-6. In some embodiments, the modifier is a "viscosity modifier" and is included to adjust
viscosity (e.g., to increase/decrease viscosity of the homogeneous mixture or nanoemulsion). In some embodiments, the viscosity modifier is a "viscosity reduction agent" and is included to reduce the viscosity (e.g., of the homogeneous mixture, aqueous solution, and/or nanoemulsion).
In some embodiments, suitable hydrophobic agents are oils, lipids, or other compositions that are non-miscible with water or have low miscibility with water. In some embodiments, a hydrophobic agent is an active agent (e.g., having a desired property for which the nanoemulsion is a delivery vehicle). In some embodiments, the hydrophobic agent is the active agent of the nanoemulsion. Suitable hydrophobic agents include, but are not limited to, oils of the type of mineral oils, vegetable oils, animal oils, essential oils, synthetic oils, or mixtures thereof. In some embodiments, a hydrophobic agent is an oil rich in triglycerides, such as safflower oil, soybean oil, sesame oil, camellia oil, cotton seed oil, medium chain triglycerides, their mixtures or mixtures with other vegetable oils. In some embodiments, a hydrophobic agent is a poorly water-soluble drugs, such as: paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole,
celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone, etc. In some embodiments, a hydrophobic agent comprises one or more essential oils, such as those derived from berries (e.g., allspice, juniper, etc.), seeds (e.g., almond, anise, buchu, celery, cumin, nutmeg oil, etc.), bark (e.g., cassia, cinnamon, sassafras, etc.), wood
(e.g., camphor, cedar, rosewood, sandalwood, agarwood, etc.), rhizome (e.g., galangal, ginger, etc.), leaves (e.g., basil, bay leaf, buchu, cinnamon, common sage, eucalyptus, guava, lemon grass, melaleuca, oregano, patchouli, peppermint, pine, rosemary, spearmint, tea tree, thyme, tsuga, wintergreen, etc.), resin (e.g., benzoin, copaiba, frankincense, myrrh, etc.), flowers (e.g., cannabis, chamomile, clary sage, clove, scented geranium, hops, hyssop, jasmine, lavender, manuka, marjoram, orange, rose, ylang-ylang, etc.), peel (e.g., bergamot, grapefruit, lemon, lime, orange, tangerine, etc.), root (e.g., valerian, etc.). In some embodiments, a hydrophobic agent is peptide or protein drug such as: insulin, leuprorelin, bortezomib, goserelin, bivalirudin, eptifibatide, glatiramer, liraglutide, telaprevir, boceprevir, icatibant, etc.
In some embodiments, the active agent is the hydrophobic agent. In some embodiments, an additional active agent is added. In some embodiments, an active agent is dissolved or placed in solution in a hydrophobic carrier (e.g., vegetable oil, etc.).
In embodiments described throughout, reagents, solutions, mixtures, etc. are mixed, stirred, shaken, or otherwise combined. Unless otherwise specified, combination of reagents occurs passively (e.g., by diffusion), or reagents are actively combined by mechanical intervention (e.g., stirring, agitating, etc.) or other processes (e.g., soni cation, etc.). In some embodiments in which stirring is employed, the rate of stiring is at least 1 rpm and not exceeding 5000 rpms (e.g., 1 rpm, 2 rpms, 5 rpms, 10 rpms, 20 rpms, 50 rpms, 100 rpms, 200 rpms, 500 rpms, 1000 rpms, 2000 rpms, 2500 rpms, 3000 rpms, 4000, rpms, 5000 rpms or any suitable ranges therebetween). In some embodiments, sonication is employed (e.g., when initially mixing the reagents to form the homogeneous mixture). In some embodiments, vigorous stirring (e.g., 1000-2000 rpms, about 1500 rpms, etc.) is employed during the addition of aqueous phase to the homogeneous mixture. In some embodiments, gentle stirring (e.g., 100 to 600 rpms (e.g., 100 rpms, 200 rpms, 300 rpms, 400 rpms, 500 rpms, 600 rpms or any suitable ranges therebetween (e.g., 200-500 rpms))) is employed (e.g., to induce a reduction in nanodroplet size).
Formation of homogeneous mixture (step Oa)
In some embodiments, formation of nanoemulsion according to the embodiments described herein utilizes a homogeneous mixture comprising at least a hydrophobic agent (which is mixed with an aqueous solution (e.g., in a subsequent step)).
In some embodiments, methods comprise combining (e.g., mixing) a nonionic surfactant (e.g., Tween 80), a co-surfactant (e.g., PEG-400), and/or a modifier (e.g., propylene glycol isopropyl alcohol, etc.) with a hydrophobic agent (e.g., a hydrophobic agent having a desired property (e.g., cosmetic property, wellness- promotion property, therapeutic/prophalactic property, etc.). In some embodiments, the nonionic surfactant, co-surfactant, and/or modifier are combined into a homogeneous mixture before adding the hydrophobic agent. In some embodiments, the nonionic surfactant, co-surfactant, modifier, and hydrophobic agent, and added together and then homogenized. In some embodiments, nonionic surfactant, co- surfactant, modifier, and/or hydrophobic agent are mixed (e.g., stirred) or allowed to mix at ambient temperature and atmospheric pressure to provide homogeneous mixture.
Formation of an aqueous solution (step Ob)
In some embodiments, formation of nanoemulsion according to the embodiments described herein utilizes an aqueous solution (which is mixed with a homogeneous mixture comprising a hydrophobic agent (e.g., in a subsequent step)). In some embodiments, the aqueous solution described in embodiments herein comprises, consists, or consists essentially of water (with common salt, metal, and oxide impurities) or distilled water. In some embodiments, the aqueous solution further comprises one or more suitable buffers, salts, etc. The aqueous solution is not limited by the type or presence of cations (e.g., (NH4+, Ca , Mg , Na , Fe , Fe , etc.), anions (CI", Br", C03 2", P04 3", S04 2", etc.), buffers (e.g., TRIS, MOPS, HEPES, etc.), or other solutes in the aqueous solution, unless an embodiment specifies otherwise.
In some embodiments, the aqueous solution further comprises a surfactant, co- surfactant, and/or modifier. In some embodiments, one or more of a surfactant, co- surfactant, and/or modifier are mixed with water and any other suitable solutes to generate an aqueous solution. In some embodiments herein that refer to an aqueous solution, an aqueous mixture (e.g., water and one or more undissolved components (e.g., surfactant, co-surfactant, and/or modifier) is used. Formation of nanoemulsion (step 1)
In some embodiments, an aqueous solution (e.g., water, distilled water, water and buffer/salt) is added to the homogeneous mixture (e.g., at ambient temperature (e.g., 18 °C, 19 °C, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, 25 °C, 26 °C, 27 °C, 28 °C, and any suitable ranges therein (e.g., 20-26 °C, 22-24 °C)) and atmosphere pressure (e.g., 684-836 Torr (e.g., 684 Torr, 700 Torr, 716 Torr, 732 Torr, 748 Torr, 764 Torr, 780 Torr, 796 Torr, 812 Torr, 828 Torr, 836 Torr, or ranges therebetween)) ). In some embodiments, the aqueous solution is added with stirring, shaking, or other mechanical mixing. In some embodiments, the aqueous solution is added (e.g., dropwise) over the course of at least 5 minutes (e.g., 5 mia, 10 mia, 15 mia, 20 mia, 25 mia, 30 mia, 35 mia, 40 mia, 45 mia, 50 mia, 55 mia, 60 mia, 80 mia, 100 mia, 120 mia, >120 mia, or any suitable ranges therein (e.g., 20-40 mia, etc.). In some embodiments, aqueous solution is added at a suitable rate, as described herein (e.g., <5 g/mia, <2 g/mia, <1 g/mia, <0.5 g/mia, <0.2 g/min, etc.). In some embodiments, a fixed volume of aqueous solution is added (e.g., to achieve a
particular ratio (e.g., with respect to another ingredient (e.g., surfactant, co-surfactant, modifier, hydrophobic agent, etc.)). In some embodiments, aqueous solution is slowly added to the homogeneous mixture until a nanoemulsion forms (e.g., without concern as to the volume of the water added).
In other embodiments, the homogeneous mixture is added to an aqueous solution (e.g., water, distilled water, water and buffer/salt). In some embodiments, the homogeneous mixture is added with stirring, shaking, or other mechanical mixing. In some embodiments, the aqueous solution is added (e.g., drop wise) over the course of at least 5 minutes (e.g., 5 min., 10 min., 15 min., 20 min., 25 min., 30 min., 35 min., 40 min., 45 min., 50 min., 55 min., 60 min., 80 min., 100 min., 120 min., >120 min., or any suitable ranges therein (e.g., 20-40 min., etc.)). In some embodiments, the homogeneous mixture is added at a suitable rate, as described herein (e.g., <5 g/min., <2 g/min., <1 g/min., <0.5 g/min., <0.2 g/min, etc.). In some embodiments, a fixed volume of homogeneous mixture is added to a fixed volume of homogeneous mixture. In some embodiments, homogeneous mixture is slowly added to a fixed volume of aqueous solution until a nanoemulsion forms (e.g., without concern as to the volume of the homogeneous mixture added).
In some embodiments, the end product of the above-described mixing of the homogenous mixture and aqueous solution is a nanoemulsion. In some embodiments, the nanoemulsion is translucent. In some embodiments, the end product of the initial addition/mixing of the homogenous mixture and aqueous solution is not transparent. In some embodiments, the translucency but not transparency of the nanoemulsion indicates moderately-sized nanodroplets (e.g., 200 nm, 180 nm, 160 nm, 140 nm, 120 nm, 100 nm, 80 nm, 60 nm, 40 nm, or any suitable ranges therebetween (e.g., 60-120 nm). In some embodiments, a nanoemultion produced by slow addition (with mixing/stirring) of aqueous solution to homogenous mixture (or vice versa) exhibits moderately-sized mean or median nanodroplets. In some embodiments, such a nanoemulsion is produced in less than 1 hour (e.g., 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or any suitable ranges therein) of combining aqueous solution and homogenous mixture.
In some embodiments, the nanoemulsions comprising moderately-size nanodroplets are termed first-stage nanoemulsions (e.g., having not yet been exposed to further mixing/stirring to produce small (e.g., <40 nm) or ultrasmall (e.g., <10 nm) nanodroplets).
Reduction of nanodroplet size (step 2)
In some embodiments, following the combining of an aqueous solution and homogeneous mixture to produce a nanoemulsion (e.g., of moderately-size nanodroplets, first-stage nanoemulsion, etc.), continued mixing (e.g., stirring, agitation, etc.) of the nanoemulsion at ambient temperature and atmospheric pressure. In some embodiments, mixing is continued in the same vessel. In some embodiments, mixing is continued in a different vessel. In some embodiments, continued mixing produces a highly clear and transparent. In some embodiments, the transparency of the nanoemulsion indicates significant reduction of nanodroplet size (e.g., small (e.g., <40 nm) or ultrasmall (e.g., <10 nm) nanodroplets). In some embodiments, following initial formation of the nanoemulsion (e.g., translucent nanoemulsion, moderately- sized nanodroplets, etc.) continued mixing is carried out for at least 30 minutes (e.g., 30 min., 45 min., 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or more, or any suitable ranges therein (e.g., >4 hours, 2-24 hours, etc.)). In some embodiments, mixing is carried out by vigorous stirring. In some embodiments, mixing is carried out by moderate intensity stirring. In some embodiments, mixing is carried out by gently stirring. Other embodiments
In some embodiments, co-surfactant and modifier are present in a
homogeneous mixture (or in an aqueous solution) to reduce viscosity. In some embodiments, this is particularly important for the preparation of nanoemulsions at ambient temperature (e.g., to save cost, for nanoemulsions made of reagents (e.g., hydrophobic agents) that do not tolerate elevated temperatures, etc.), because heat cannot be added to the system to reduce viscosity; although the embodiments are not limited to any particular mechanism of action and an understanding of the mechanism of action is not necessary to practice such embodiments. However, in some embodiments, for the ingredients (e.g., hydrophobic agents) that can tolerate the higher than room temperature, only one nonionic surfactant (e.g., no co-surfactant and/or modifier) is used, for example, in preparation of the homogenous mixture, first-stage nanoemulsion, and/or final transparent nanoemulsion product. In some embodiments, the use of elevated temperature (e.g., 30°C or greater
(e.g., >30°C, >35°C, >40°C, >45°C, >50°C, >55°C, >60°C, >65°C, >70°C, or more),
etc.) and atmosphere pressure (or elevated pressure (e.g., >800 Torr, >810 Torr, >820 Torr, >830 Torr, >840 Torr, >850 Torr, >875 Torr, >900 Torr, >950 Torr, >1000 Torr, >1100 Torr, >1200 Torr, 1300 Torr, 1400 Torr, 1500 Torr) allows for formation of the first stage nanoemulsion with a single surfactant (e.g., no co-surfactant and/or modifier). This translucent nanoemulsion is then stirred at ambient temperature (or at elevated temperature) and atmosphere pressure (or elevated pressure) for a time ranging from hours (e.g., 2-20 hours) to days (e.g., 1 to 6 days) to generate the highly clear and transparent nanoemulsion. In some embodiments, this single-surfactant formulation provides a very simple nanoemulsion system for further modification including combination with other ingredients.
Formulation
In some embodiments, the compositions described herein are provided as pharmaceutical, therapeutic, skin-care, hair-care, beauty, health, and/or wellness compositions. Compositions can be administered in a number of ways depending upon whether local or systemic administration is desired. Administration can be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
Compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional carriers; aqueous, powder, or oily bases;
thickeners; and the like can be necessary or desirable. Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. Compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions that can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
Formulations, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the appropriate industries. Compositions can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention can also be formulated as suspensions in aqueous, non-aqueous, oil-based, or mixed media. Suspensions can further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers. Compositions can be formulated and used as foams.
Dosing and administration regimes may be tailored by a clinician or other individual skilled in the appropriate field, based upon well-known considerations including, but not limited to, the desired level of effect, the practical level of effect obtainable, side effects, cost, etc. Dosing may be once per day or multiple times per day for one or more consecutive days.
EXAMPLES
Example 1
Preparation of the black raspberry essential oil oil-in-water nanoemulsion of black raspberry essential oil
The mixture of black raspberry essential oil (lOOmg), Tween 80 (0.22g), PEG-
400 (0.13g) and propylene glycol (0.1 lg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 2 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 5 days, a highly clear and transparent naonemulsion was obtained.
Example 2
Preparation of the black raspberry essential oil oil-in-water nanoemulsion of black raspberry essential oil
The mixture of black raspberry essential oil (200mg), Tween 80 (0.44g), PEG- 400 (0.09g) and propylene glycol (0.20g) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 4 g.
A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 2 days, a highly clear and transparent nanoemulsion was obtained. Example 3
Preparation of the black raspberry essential oil oil-in-water nanoemulsion of black raspberry essential oil
The mixture of black raspberry essential oil (lOOmg), Tween 80 (0.20g), PEG- 400 (0.1 Og) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent nanoemulsion was obtained.
Example 4
Preparation of the oil-in-water nanoemulsion of pink grapefruit essential oil
The mixture of pink grapefruit essential oil (lOOmg), Tween 80 (0.20g), PEG- 400 (0.1 Og) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 2 days, a highly clear and transparent naonemulsion was obtained.
Example 5
Preparation of the oil-in-water nanoemulsion of pink grapefruit essential oil
The mixture of pink grapefruit essential oil (lOOmg), Tween 80 (0.20g), PEG- 400 (0.05g) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 3 hours, a highly clear and transparent naonemulsion was obtained.
Example 6
Preparation of the oil-in-water nanoemulsion of mango essential oil
The mixture of mango essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0. lOg) and isopropyl alcohol (91% in water, 0. lOg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 3 days, a highly clear and transparent naonemulsion was obtained.
Example 7
Preparation of the oil-in-water nanoemulsion of mango essential oil
The mixture of mango essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0.06g) and isopropyl alcohol (91% in water, 0. lOg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
Example 8
Preparation of the oil-in-water nanoemulsion of coconut essential oil
The mixture of coconut essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0. lOg) and isopropyl alcohol (91% in water, 0. lOg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
Example 9
Preparation of the oil-in-water nanoemulsion of vanilla essential oil
The mixture of vanilla essential oil (lOOmg), Tween 80 (0.20g), PEG-400 (0.1 Og) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
Example 10
Preparation of the oil-in-water nanoemulsion of orange oil
The mixture of orange oil (lOOmg), Tween 80 (0.21g), PEG-400 (0.24g) and isopropyl alcohol (91% in water, 0.1 lg) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 1.5 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure overnight, a highly clear and transparent naonemulsion was obtained.
Example 11
Preparation of the oil-in-water nanoemulsion of orange oil
The mixture of orange oil (lOOmg), Tween 80 (0.21g), PEG-400 (0.05g) and isopropyl alcohol (91% in water, 0.1 Og) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 2 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
Example 12
Preparation of the oil-in-water nanoemulsion of orange oil
The mixture of orange oil (190mg), Tween 80 (0.29g), PEG-400 (0.29g) and ethyl alcohol (absolute, 0.22g) was stirred at ambient temperature and atmosphere
pressure for 5 min. Water (distilled) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 3.2 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 4 hours, a highly clear and transparent naonemulsion was obtained.
Example 13
Preparation of the oil-in-water nanoemulsion of orange oil
The mixture of orange oil (1.0 g) and Tween 80 (2.0 g) was stirred at 50 °C and atmosphere pressure for 5 min. Water (distilled) was added very slowly at 50 °C in 30 min. and atmosphere until the total mass of the mixture reached 20 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure overnight, a highly clear and transparent naonemulsion was obtained. Naoemulsion droplet size is at 4.9±1.1 nm (method is DLS, Dynamic Light Scattering).
Example 14
Preparation of the oil-in-water nanoemulsion of orange oil
The mixture of orange oil (29.0 g) and alkyl glucoside (C8-C16, 50% wt aqueous solution, 58 g) was stirred at 50 °C and atmosphere pressure for 15 min.
Water (distilled) was added very slowly at 50 °C in 60 min. and atmosphere until the total mass of the mixture reached 575 g. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure overnight, a highly clear and transparent naonemulsion was obtained.
Example 15
Preparation of the oil-in-water nanoemulsion of Clofazimine (e.g., for development of anti-tuberculosis drug using an easy-to-use inhalation delivery system)
The mixture of Clofazimine (100 mg) in soybean oil (1.0 g) was stirred at 50 °C for 2 days. PEG-400 (0.1 g) were added and stirred at 50 °C and atmosphere pressure for 1 hour. The mixture of Tween 80 (4.0 g) and water (distilled, 4.0 g) was stirred at 50 °C in 15 min. The above mentioned mixture of Clofazimine, soybean oil
and PEG-400 was added very slowly at 50 °C in 30 min. The mixture was stirred at ambient temperature and atmosphere pressure overnight. The mixture was centrifuged and the highly clear and transparent nanoemulsion top was separated. The HPLC results showed the concentration of Clofazimine in this nanoemulsion is 0.45 mg/mL. Naoemulsion droplet size is at 6.5±1.1 nm (method is DLS, Dynamic Light
Scattering).
Example 16
Preparation of the oil-in-water nanoemulsion of Paclitaxel (Taxol as trade name for anti-cancer medicine)
Paclitaxel (22 mg) was dissolved in the mixture of Tween 80 (0.88 g), PEG- 400 (1.23 g) and ethyl alcohol (absolute, 0.6 g) by sonication for 5 min. Then, to this solution, water (distilled) was added very slowly at ambient temperature and atmosphere. When the total mass reached 3 g, a translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure overnight, a highly clear and transparent naonemulsion was obtained.
Example 17
Preparation of the oil-in-water nanoemulsion of peppermint oil
The mixture of peppermint oil (40.3g), Tween 80 (81.4g), PEG-400 (14.2g) and propylene glycol (14.0g) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (filtered) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 400 g.
Potassium sorbate (0.46 g, 24.9% aqueous solution) was added at rt. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 2 days, a highly clear and transparent naonemulsion was obtained.
Table 1. Results of particle size measurement'
Time Particle size (percentage)
15 min. 19.7 ± 7.8 nm (91.8%) 588 ± 224 nm (3.7%) 4400 ± 936 nm (4.5%)
1 h 13.7 ± 3.6 nm (84.1%) 1722 ± 556 nm (8.0%) 4155 ± 995 nm (7.9%)
20 h 16.2 ± 4.4 nm (89.9%) 2825 ± 123 6nm (10.1%)
48 h 15.8 ± 5.1 nm ( 100%)
Instrument: Malvern Zetasizer Nano-S90
Example 18
Preparation of the oil-in-water nanoemulsion of lavender oil
The mixture of lavender oil (286g), Tween 80 (572g), PEG-400 (98g) and propylene glycol (198g) was stirred at ambient temperature and atmosphere pressure for 10 min. Water (filtered) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 2.8kg. Potassium sorbate (8g) was added at rt. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 20 h, a highly clear and transparent naonemulsion was obtained.
Table 2. Results of particle size measurement'
Time Particle size (percentage)
30 min. 19.0 ± 5.5 nm (92.8%) 718 ± 195 nm (3.1%) 4853 ± 703 nm (4.1%)
20 h 16.4 ± 3.6 nm (100%)
instrument: Malvern Zetasizer Nano-S90
Example 19
Preparation of the oil-in-water nanoemulsion of lemon oil The mixture of lemon oil (40.0g), Tween 80 (81. Og), PEG-400 (14.2g) and propylene glycol (28.5g) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (filtered) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 400 g. Potassium sorbate (0.96 g, 24.9% aqueous solution) was added at rt. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and
atmosphere pressure for 2 days, a highly clear and transparent naonemulsion was obtained. Table 3. Results of particle size measurement'
Time Particle size (percentage)
5 min. 19.3 ± 5.0 nm (65.9%) 418 ± 141 nm (31.6%) 5186 ± 483 nm (2.5%)
12 h 14.6 ± 3.4 nm (65.8%) 375 ± 114 nm (32%) 4155 ± 995 nm (7.9%)
48 h 12.0 ± 3.8 nm ( 100%)
*Instrument: Malvern Zetasizer Nano-S90
Example 20
Preparation of the oil-in-water nanoemulsion of tea tree oil
The mixture of tea tree oil (40g), Tween 80 (80g), PEG-400 (14g) and propylene glycol (28g) was stirred at ambient temperature and atmosphere pressure for 5 min. Water (filtered) was added very slowly in 30 min. at ambient temperature and atmosphere until the total mass of the mixture reached 400 g. Potassium sorbate (1.12 g) was added at rt. A translucent nanoemulsion was formed. Further stirring of this translucent nanoemulsion at ambient temperature and atmosphere pressure for 7 days, a highly clear and transparent naonemulsion was obtained.
Table 4. Results of particle size measurement*
Time Particle size (percentage)
30 min. 18.3 ± 5.0 nm (86.9%) 347 ± 94.4 nm (9.5%) 5131 ± 524 nm (3.6%)
3 d 15.2 ± 2.8 nm (61.3%) 437 ± 82.3 nm (38.7%)
7 d 14.2 ± 2.5 nm (100%)
Instrument: Malvern Zetasizer Nano-S90
Various modification and variation of the described methods and compositions of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention
that are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.
Claims
1. A method for preparing a nanoemulsion comprising:
(a) combining: (i) an aqueous solution and (ii) a homogeneous mixture comprising a nonionic surfactant and hydrophobic agent to form a nanoemulsion; and
(b) stirring the nanoemulsion to reduce average diameter of droplets in the nanoemulsion.
2. The method of claim 1 , wherein the aqueous solution and the homogeneous mixture are combined at a sufficiently slow enough rate to allow formation of the nanoemulsion.
3. The method of claim 1 , wherein the nanoemulsion is stirred for greater than 1 hour to reduce average diameter of droplets in the nanoemulsion.
4. The method of claim 1 , wherein one or both of steps (a) and (b) is performed at ambient temperature and atmospheric pressure.
5. The method of claim 4, wherein steps (a) and (b) are performed at ambient temperature and atmospheric pressure.
6. The method of claim 1 , wherein the aqueous solution is distilled water.
7. The method of claim 1 , wherein the aqueous solution comprises buffer and/or salt.
8. The method of claim 1 , wherein the nanoemulsion formed in step (a) comprises an average droplet diameter of 40-150 nm.
9. The method of claim 1 , wherein the average droplet diameter following step (b) is less than 20 nm.
10. The method of claim 1 , wherein the average droplet diameter following step (b) is less than 10 nm.
1 1. The method of claim 1 , wherein the average droplet diameter following step (b) is less than 5 nm.
12. The method of claim 1 , wherein the hydrophobic agent is
physiologically compatible.
13. The method of claim 12, wherein the hydrophobic agent is an oil.
14. The method of claim 1 , wherein the surfactant is Tween 80.
15. The method of claim 1 , wherein the aqueous solution comprises a modifier and/or co-surfactant.
16. The method of claim 1 , wherein the homogeneous mixture further comprises a modifier and/or co-surfactant.
17. The method of claim 15 or 16, the modifier is a viscosity modifier.
18. The method of claim 17, wherein the viscosity modifier is a viscosity- reduction agent.
19. The method of claim 18, wherein the viscosity-reduction agent is selected from the group comprising ethyl alcohol, isopropyl alcohol, and propylene glycol.
20. The method of claim 15 or 16, the co-surfactant is PEG-400.
21. A composition comprising a nanoemulsion produced by the method of one or claims 1 -20.
A composition comprising a nanodroplet from a composition of claim
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158568P | 2015-05-08 | 2015-05-08 | |
US62/158,568 | 2015-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016182926A1 true WO2016182926A1 (en) | 2016-11-17 |
Family
ID=57249370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/031263 WO2016182926A1 (en) | 2015-05-08 | 2016-05-06 | Preparation of nanoemulsions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016182926A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3061010A1 (en) * | 2016-12-23 | 2018-06-29 | L'oreal | NANOEMULSIONS BASED ON POLAR OIL |
WO2019110099A1 (en) * | 2017-12-06 | 2019-06-13 | Qrumpharma Inc. | Inhalable clofazimine formulation |
WO2020056525A1 (en) * | 2018-09-21 | 2020-03-26 | Hai Beverages Inc. | Water soluble cannabinoid beverage composition |
CN114340402A (en) * | 2019-09-04 | 2022-04-12 | 百事可乐公司 | Method for preparing transparent emulsion |
CN114668147A (en) * | 2022-03-25 | 2022-06-28 | 华南农业大学 | A kind of Melaleuca alternifolia composite essential oil microemulsion and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US20060100288A1 (en) * | 2004-11-09 | 2006-05-11 | Novagali Pharma Sa | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
US20090324727A1 (en) * | 2006-12-22 | 2009-12-31 | Biofrontera Bioscience Gmbh | Nanoemulsion |
US20100305218A1 (en) * | 2007-11-28 | 2010-12-02 | Timothy James Wooster | Nanoemulsions |
US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
-
2016
- 2016-05-06 WO PCT/US2016/031263 patent/WO2016182926A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US20060100288A1 (en) * | 2004-11-09 | 2006-05-11 | Novagali Pharma Sa | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
US20090324727A1 (en) * | 2006-12-22 | 2009-12-31 | Biofrontera Bioscience Gmbh | Nanoemulsion |
US20100305218A1 (en) * | 2007-11-28 | 2010-12-02 | Timothy James Wooster | Nanoemulsions |
US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3061010A1 (en) * | 2016-12-23 | 2018-06-29 | L'oreal | NANOEMULSIONS BASED ON POLAR OIL |
WO2019110099A1 (en) * | 2017-12-06 | 2019-06-13 | Qrumpharma Inc. | Inhalable clofazimine formulation |
WO2020056525A1 (en) * | 2018-09-21 | 2020-03-26 | Hai Beverages Inc. | Water soluble cannabinoid beverage composition |
CN114340402A (en) * | 2019-09-04 | 2022-04-12 | 百事可乐公司 | Method for preparing transparent emulsion |
CN114668147A (en) * | 2022-03-25 | 2022-06-28 | 华南农业大学 | A kind of Melaleuca alternifolia composite essential oil microemulsion and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shaker et al. | Nanoemulsion: A review on mechanisms for the transdermal delivery of hydrophobic and hydrophilic drugs | |
KR101884083B1 (en) | Nanoemulsions having reversible continuous and dispersed phases | |
CN101583339B (en) | Compositions comprising macromolecular assemblies of lipid and surfactant | |
Algahtani et al. | Preparation and characterization of curcumin nanoemulgel utilizing ultrasonication technique for wound healing: In vitro, ex vivo, and in vivo evaluation | |
WO2016182926A1 (en) | Preparation of nanoemulsions | |
JP5513713B2 (en) | Compositions that produce non-layered dispersions | |
JP5563723B2 (en) | W / O / W emulsion having stability over time and method for producing the same | |
EP3278789A1 (en) | Cosmetic composition with multiple emulsion formulation having lamellar liquid crystal structure | |
JP2011518184A5 (en) | ||
CN108888595A (en) | A kind of nano-emulsion preparation containing hydroxytyrosol and its freeze-dried preparation method | |
CN101822638A (en) | Nano-emulsion of stilbene compound and preparation method thereof | |
AU2001280306A1 (en) | Combination compositions | |
de Oliveira et al. | Self-emulsifying systems for delivery of bioactive compounds from natural origin | |
Yap et al. | Plant essential oil nanoemulgel as a cosmeceutical ingredient: A review | |
CN101998828A (en) | Pharmaceutical solutions and method for solubilizing therapeutic agents | |
CN107875038B (en) | Olive oil microemulsion preparation and application thereof as whitening sunscreen agent | |
JP2011213679A (en) | Transparent or translucent composition for external application | |
Sun et al. | The Current Status, Hotspots, and Development Trends of Nanoemulsions: A Comprehensive Bibliometric Review | |
JPH05503695A (en) | pharmaceutical formulations | |
TW200914063A (en) | The formulation of skin permeable polyphenols-encapsulated nanoemulsion | |
AU2016247173B2 (en) | Nanoemulsions having reversible continuous and dispersed phases | |
JPH0366618A (en) | Pharmaceutical compound | |
JP2011231109A (en) | Composition | |
BR102023002791A2 (en) | NANOSTRUCTURED AQUEOUS FORMULATION OF PROPOLIS EXTRACT AND ITS USES | |
WO2023164559A1 (en) | Anti-inflammatory drug-cannabinoid-comprising nanoemulsions and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16793263 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16793263 Country of ref document: EP Kind code of ref document: A1 |